



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	10/534,291	Case No.: 21145YP
Filed:	May 9, 2005	
For:	PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

Examiner:
Yong Liang
Chu

Art Unit:
1626

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF MING-TAIN LAI UNDER 37 C.F.R. § 1.132

I, Ming-Tain Lai, hereby declare as follows:

1. I am a citizen of the United States, and am over 21 years of age. A copy of my curriculum vitae is attached at Exhibit A.

2. In October 2002, HPLC assays of BACE1 (β -site amyloid precursor protein cleaving enzyme) were regularly conducted under my control and supervision at my laboratory at Merck's facility in West Point, Pennsylvania. Among the compounds tested were a series of phenylcarboxamide compounds, which were designed and synthesized by medicinal chemists working at Merck's West Point, Pennsylvania laboratories.

3. The BACE HPLC assay, which was a standard Merck assay, was developed by me and other biologists at Merck's West Point laboratories. The assay was designed to detect cleavage of a coumarin-labeled 10 mer peptide (coumarin-REVNFEVEFR), using either a Waters 2690 Alliance or Alliance HT HPLC instrument. The assay procedure is generally described in International application no. WO 2004/099376.

4. The BACE HPLC assays were conducted according to the following procedure. A reaction buffer was formed of the following ingredients:

MATERIAL	AMOUNT (μ l)
4X NaOAc, 200mM, pH 4.5	25
BSA, 1mg/ml (Bovine Fraction V, Sigma #9647)	2.0
EDTA, 150mM, pH 4.5	10
10% CHAPS(Pierce, #28300)	2.0
Deferoxamine Mesylate, 50mM (Sigma, #D9533)	2.0
b-BACE1 (20nM, 20mM Tris, pH 7.2)	10
H ₂ O	31

5. 8 μ l of compound (in DMSO) was added to 90 μ l of the reaction buffer, and the resulting mixture was incubated at room temperature with shaking for 30 minutes.

6. Thereafter, 2 μ l of the substrate coumarin-CO-REVNFEVEFR (50 μ M) (as described in WO 2004/099376) was added to the mixture. The resulting mixture was maintained at 25°C for 30 minutes with shaking. The reaction was quenched with 25 μ l of 1M Tris-HCl pH8.0.

7. Samples of the mixture were then centrifuged in a tabletop centrifuge at 15K. For analysis with the Alliance HPLC instrument, 60 μ l of the supernatant was removed. For analysis with the Alliance HT instrument, 50 μ l of the sample was passed through a filtration system (Millipore, 0.22 μ m hydrophilic) prior to HPLC analysis.



8. The HPLC conditions involved an Xterra RP18 column (3.5 μ m, 2.1 x 150 mm). The mobile phase consisted of solvent A (0.05% trifluoro acetic acid in water) and solvent B (0.045% trifluoroacetic acid in acetonitrile), according to the following gradient:





Time (minutes)	Percent Solvent B
0	19
3	25
4	95
5	19

Sample injection volumes were 50 μ L for the Alliance and 25 μ L for the Alliance HT. Detection was measured at 340 nm (excitation) and 440 nm (emission). Percent inhibition was measured according to the following formula:

$$(1 - (\text{area of product peak of (E+S+compound)} / \text{area of product peak of (E+S)})) \times 100$$

9. The results of the HPLC assay for selected phenylcarboxamide compounds are set forth below:

COMPOUND	Date of Testing	Inhibition of BACE1 (nM)
	June 7, 2002	3
	June 7, 2002	220

	June 10, 2002	1
	July 9, 2002	3.5
	July 17, 2002	46
	October 7, 2002	11

10. I further declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements are made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the instant application or any patent issued thereon.

Ming-Tain Lai

Dated: May 8, 2006



CURRICULUM VITAE OF MING-TAIN LAI

PERSONAL

- A. Name: Ming-Tain Lai
- B. Home Address: 52 Douglass Road
Lansdale, PA 19446

II. EDUCATION:

School	Dates	Major	Degree
Tunghai University Taiwan	1977-1981	Chemistry	B.S.
National Taiwan Normal University, Taiwan	1981-1983	Analytical Chemistry	M.S.
University of Minnesota	1987-1992	Bioorganic Chemistry	Ph.D.

III. MRL EMPLOYMENT HISTORY

<u>Title</u>	<u>From</u> - <u>To</u>
Research Fellow	8/30/01 - present
Senior Research Biochemist	8/30/95 - 8/30/01

IV. NON-MERCK EMPLOYMENT HISTORY

Postdoctoral Research Associate, 1992-1995
Massachusetts Institute of Technology
Supervisor: Professor JoAnne Stubbe

V. SOCIETY MEMBERSHIPS

American Chemical Society

VI. PUBLICATIONS IN PEER REVIEWED JOURNALS

1. **Lai, M-t.**; Shih, J-S., "Mercury (II) and Silver (I) Ion-Selective Electrodes Based on Dithia Crown Ether," *Analyst* **1986**, *111*, 891-895.
2. **Lai, M-t.**; Lin, W-M.; Chu, Y-H.; Chen, Y. S-l.; Kong, K-S.; Chen, C-w., "The Mechanism of Color Reversion in Soybean Salad Oil," *J. Am. Oil Chem. Soc.* **1989**, *66*, 565-571.
3. **Lai, M-t.**; Liu, H-w., "Inactivation of General Acyl-CoA Dehydrogenase by Enantiomerically Pure (Methylenecyclopropane)acetyl-CoA and Its Implication for This Enzyme-Catalyzed Reaction," *J. Am. Chem. Soc.* **1990**, *112*, 4034-4035.
4. **Lai, M-t.**; Liu, L-d.; Liu, H-w., "Mechanistic Study on the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin A," *J. Am. Chem. Soc.* **1991**, *113*, 7388-7397.

5. **Lai, M.-t.**; Oh, E.; Shih, Y.; Liu, H.-w., "Synthesis of Enantiomerically Pure (Methylenecyclopropane)acetyl-CoA: the Causative Agent of Jamaican Vomiting Sickness," *J. Org. Chem.* **1992**, *57*, 2471-2476.
6. **Lai, M.-t.** ; Liu, H.-w., "New Evidence Supporting A Radical Mechanism of the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin," *J. Am. Chem. Soc.* **1992**, *114*, 3160-3162.
7. **Lai, M.-t.**; Oh, E.; Liu, H.-w., "Studies of the Inactivation of General Acyl-CoA Dehydrogenase (1*R*)- and (1*S*)-(Methylenecyclopropane)acetyl-CoA," *Bioorg & Med. Chem. Lett.* **1992**, *2*, 1423-1426.
8. **Lai, M.-t.**; Li, D.; Oh, E.; Liu, H.-w., " Inactivation of Medium-Chain Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin: Characterization of the Major Turnover Product and Evidence Suggesting an Alternative Flavin Modification Pathway," *J. Am. Chem. Soc.* **1993**, *115*, 1619-1628.
9. Thornburg, L.D.; **Lai, M.-t.**; Wishnok, J. S.; Stubbe, J., " A Non-Heme Iron Protein with Heme Tendencies: An Investigation of the Substrate Specificity of Thymine Hydroxylase," *Biochemistry* **1993**, *32*, 14023-14033.
10. Horner, J. H.; Johnson, C. C.; **Lai, M.-t.**; Liu, H.-w.; Martin-Esker, A. A.; Newcomb, M.; Oh, E., " Highly Regioselective and Rapid Ring Opening of the (Methylenecyclopropyl)methyl Radical," *Bioorgan. & Med. Chem. Lett.* **1994**, *4*, 2693-2696.
11. Taoka, S.; Padmakumar, R.; **Lai, M.-t.**; Liu, H.-w.; Banerjee, R., " Inhibition of the Human Methylmalonyl-CoA Mutase by Various CoA Esters," *J. Biol. Chem.* **1994**, *269*, 31630-31634.
12. **Lai, M.-t.**; Wu, W.; Stubbe, J., " Characterization of a Stable, Novel Adduct Resulting from the Inactivation of Thymine Hydroxylase by 5-Ethynyluracil," *J. Am. Chem. Soc.* **1995**, *117*, 5023-5030.
13. **Lai, M.-t.**; Di Cera, E.; Shafer, J.A., "Kinetic Pathway for the Slow to Fast Transition of Thrombin: Evidence of Linked Ligand Binding at Structurally Distinct Domains," *J. Biol. Chem.* **1997**, *272*, 30275-30282.
14. Li, Y.-M.; Xu, M.; **Lai, M.-t.**; Huang, Q.; Castro, J. L.; DiMuzio-Mower, J.; Harrison, T.; Lellis, C.; Nadin, A.; Neduvilil, J. G.; Register, R.B.; Sardana, M. K.; Shearman, M. S.; Smith, A. L.; Shi, X.-P.; Yin, K.-C.; Shafer, J. A.; Gardell, S. J., Photoactivated, active site directed γ -secretase inhibitors covalently label presenilin 1 *Nature*, **2000**, *405*, 689-694.
15. Li, Y.-M.; **Lai, M.-t.**; Xu, M.; Huang, Q.; DiMuzio-Mower, J.; Sardana, M. K.; Shi, X.-P.; Yin, K.-C.; Shafer, J. A.; Gardell, S. J., Presenilin 1 is Linked with β -Secretase Activity in the Detergent Solubilized State. *Proc. Natl. Acad. Sci. USA.* **2000**, *97*, 6183-6143.
16. Shi, X.-P.; Chen E.; Yin, K.-C.; Na, S.; Garsky, V.; **Lai, M.-t.**; Li, Y.-M.; Platchek, M.; Regiater, B.; Sardana, M.; Tang, M.; Thiebeau, J.; Wood, T.; Shafer, J.; Gardell, S.J., The Pro Domain of β -Secretase Does Not Confer Strict Zymogen-like Properties But Does Assist Proper Folding of the Protease Domain. *J. Biol. Chem.* **2001**, *276*, 10366-10373.

17. Gardell, S.J.; Li, Y.M.; Xu, M.; Lai, M.-t.; Huang, Q.; Castro, J. L.; DiMuzio-Mower, J.; Harrison, T.; Lellis, C.; Nadin, A.; Neduvilil, J. G.; Register, R. B.; Sardana, M. K.; Shearman, M. S.; Smith, A. L.; Shi, X. P.; Yin, K.C.; Shafer, J. A., Photoactivated, active site directed γ -secretase inhibitors covalently label presenilin 1, in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (Iqbal K, Sisodia SS and Winblad B eds) **2001**, pp 789-798, John Wiley & Sons, LTD, West Sussex, UK

18. Xu, M.; Lai, M.-t.; Huang, Q.; Castro, J. L.; Harrison, T.; Nadin, A.; Neduvilil, J. G.; Sardana, M. K.; Shearman, M. S.; Smith, A. L.; Shafer, J. A.; Gardell, S. J.; Li, Y. M., γ -Secretase: identification and Implication for Alzheimer Disease Therapy. *Neurobiology of Aging*, **2002**, 23, 1023-1030.

19. Lai, M.-t.; Chen, E.; Crouthamel, M. C.; DiMuzio-Mower, J.; Xu, M.; Huang, Q.; Price, E.; Register, R.; Shi, X. P.; Donoviel, D. B.; Bernstein, A.; Hazuda, D.; Shafer, J. A.; Gardell, S. J.; Li, Y. M. Presenilin-1 and -2 mediated γ -secretase activities are distinct for APP processing. *J. Biol. Chem.*, **2003**, 278 (25) 22475-22481.

20. Brady, S. F.; Singh, S.; Crouthamel, M. C.; Hollow, M. K.; Coburn, C. A.; Garsky, V. M.; Bogusky, M.; Pennington, M. W.; Vacca, J. P.; Hazuda, D.; Lai, M.-t., Rational Design and Synthesis of Selective BACE 1 Inhibitors. *Bioorg. Med. Chem. Lett.*, **2004**, 14 (3), 601-604.

21. Coburn, C. A.; Stachel, S. A.; Li, Y.-M.; Rush, D. M.; Steele, T. G.; Chen-Dodson, E.; Holloway, K. M.; Xu, M.; Huang, Q.; Lai, M.-t.; DiMuzio J.; Crouthamel, M.-C.; Shi, X.-P.; Sardana, V.; Chen, Z.; Munshi, S.; Kuo, S.; Makara, G. M.; Annis, D. A.; Tadikonda, P. K.; Nash, H. M.; Vacca, J. P. Identification of a Small Molecule Non-Peptide Active Site β -Secretase Inhibitor that Displays a Non-Traditional Binding Mode for Aspartyl Proteases. *J. Med. Chem.* **2004**, 47(25), 6117-6119.

22. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Jones, K. G.; Loutzenhiser, E. F.; Gregro, A. R.; Rajapakse, H. A.; Lai, M.-t.; Crouthamel, M.-C.; Xu, M.; Tugusheva, K.; Lineberger, J. E.; Pietrak, B. L.; Espeseth, A. S.; Shi, X.-P.; Chen-Dodson, E. C.; Holloway, M. K.; Munshi, S.; Simon, A. J.; Kuo, L.; Vacca, J. P. Structure-Based Design of a Series of Potent and Selective Cell-Permeable Inhibitors of Human β -Secretase (BACE-1). *J. Med. Chem.* **2004**, 47(26); 6447-6450.

23. Shi, X.-P.; Tugusheva, K.; Bruce, J. E.; Lucas, A.; Chen-Dodson, E.; Hu, B.; Wu, G.; Price, E.; Register, R. B.; Lineberger, J.; Gate, A.; Miller, R.; Tang, M. J.; Espeseth, A.; Kahana, J.; Wolfe, A.; Crouthamel, M.-C.; Sankaranarayanan, S.; Simon, A.; Chen, L.; Lai, M.-t.; Pietrak, B.; DiMuzio, J.; Li, Y.-M.; Xu, M.; Huang, Q.; Garsky, V.; Sardana, M. K.; Hazuda, D. J. Novel Mutation introduced at the β -site of amyloid precursor protein enhances β -secretase cleavage in vitro and in cells. *J. Alzheimer's Dis.* **2005**, 7(2), 139-148.

24. Espeseth, A.; Xu, M.; Huang, Q.; Coburn, C. A.; Jones, K. L. G.; Ferrer, M.; Zuck, P.; Strulovici, B.; Price, E.; Wu, G.; Wolfe, A.; Lineberger, J.; Sardana, M. K.; Tugusheva, K.; Pietrak, B.; Crouthamel, M.-C.; Lai, M.-t.; Chen-Dodson, E.; Bazzo, R.; Shi, X.-P.; Simon, A.; Li, Y.-M.; Hazuda, D. J. Compounds that bind APP and inhibit A β processing in vitro suggest a novel approach to Alzheimer Disease therapeutics. *J. Biol. Chem.* **2005**, 280 (18), 17792-17797.

25. Pietrak, B. L.; Crouthamel, M.-C.; Tugusheva, K.; Lineberger, J. E.; Xu, M.; DiMuzio, J. M.; Steele, T.; Espeseth, A.; Stachel, S. J.; Coburn, C. A.; Graham, S. L.; Vacca, J. P.; Shi, X.-P.; Simon, A.; Haduda, D. J.; Lai, M.-t. Biochemical and cell-based assays for characterization of BACE-1 inhibitors. *Anal. Biochem.* **2005**, 342, 144-151.

26. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Crouthamel, M.-C.; Pietrak, B. L.; Lai, M.-t.; Holloway, K.; Munshi, S. K.; Graham, S. L.; Vacca, J. P. Conformationally biased P3 amide replacements of β -secretase inhibitors. *Bioorg. Med. Chem. Lett.*, in press.
27. Lai, M.-t.; Crouthamel, M. C.; DiMuzio, J.; Pietrak, B. L., M.; Donoviel, D. B.; Bernstein, A.; Gardell, S. J.; Li, Y. M.; Hazuda, D. A Presenilin- Independent Aspartyl Protease Prefers the β -42 Site Cleavage
J. Neurochem., **2006**, 96, 118-125.

VIII PATENTS

1. Nadin, A. J.; Neduvellil, J. G.; Sardana, M. K.; Shafer, J. A.; Gardell, S. J.; Lai, M.-t.; Li, Y.; Dorsey, B. D.; Dean, D. C., Investigational Compounds, Merck & Co., Inc. US Patent No. 6,753,410 B2, Granted Jun 22, 2004
2. Hazuda, D.; Dodson, E. C ; Lai, M.-t ;Xu, M. ;Shi, X.-P.; Simon, A. J. ; Wu, G. ;Li, Y. ;Register, R. B.,. Assays Using Amyloid Precursor Proteins with Modified Beta-Secretase Cleavage Sites to Monitor Beta-Secretase Activity. Filed in February, **2003**. A1
Published: 20031023 as US20030200555 A1
3. Lai, M.-t.; Crouthamel, M. C.; Brady, S. F., Beta-secretase Inhibitors, Application No. PCT/US03/15109, Filed May 14, 2003, Publication No. WO 03/099202 A2
4. Crouthamel, M. C.; Gardell, S. J.; Huang, Q.; Lai, M.-t.; Li, Y., Gamma-3 protease, Application No. PCT/US02/26969, Filed Aug. 8, 2002, Publication No. WO 03/018050 A1

IX. ABSTRACTS

1. Lai, M-t., Oh, E., Liu, L-d., Li, D., Liu, H-w., "Mechanistic Study on the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin A," XI Midwest Enzyme Chemistry Conference, University of Illinois, Chicago, IL, **1989**.
2. Lai, M-t., Oh, E., Liu, L-d., Li, D., Liu, H-w., "Mechanistic Study on the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin A" XI Midwest Enzyme Chemistry Conference, University of Illinois, Chicago, IL, **1990**.
3. Lai, M-t., Oh, E., Liu, L-d., Li, D., Liu, H-w., "Mechanistic Study on the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin A" XI Midwest Enzyme Chemistry Conference, University of Illinois, Chicago, IL, **1991**.
4. Lai, M-t., Li, D., Oh, E., Liku, H-w, "Mechanistic Study of the Inactivation of Medium-Chain Acyl-CoA Dehydrogenase (MCAD) by (methylenecyclopropyl)acetyl-CoA: Identification of a New Type of Flavin-inhibitor Adduct" XII Midwest Enzyme Chemistry Conference, University of Chicago, Chicago, IL, **1992**.

5. Li, D., Oh, E., Lai, M-t., Zhou, H-l., Becker, D.F., Stankovich, M.T., Liu, H-w., "Studies of the Inactivation of Short-Chain Acyl-CoA Dehydrogenase by Derivatives of Methylenecyclopropaneacetyl-CoA" XIII Midwest Enzyme Chemistry Conference, Loyola University Chicago, ILL, **1993**.
6. Lai, M-t., Wu, W., Stubbe, J. "Mechanism Based Inhibition of Thymine Hydroxylase by 5-Ethynyl Uracil" American Chemical Society Meeting, Washington, DC, **1994**
7. Brady, S; Bruce, J.; Singh, S.; Crouthamel, M.-C.; Holloway, K. M.; Coburn, C.; Vacca, J. P.; Shafer, J.; Hazuda, D. "Development of BACE 1 Inhibitors" 9th International Conference on Alzheimer's Disease and related Disorders, Philadelphia, PA, July 17-22, **2004**

X. INVITED LECTURES

- 3/11/93 Department of Chemistry, National Chung-Cneng University, "Mechanistic Study of the Inactivation of Medium Chain Acyl-CoA Dehydrohegenase by (methylenecyclopropane)acetyl-Co-A"
- 3/15/93 Department of Chemistry, National Chiao-Tung University, "Mechanistic Study of the Inactivation of Medium Chain Acyl-CoA Dehydrogenase by (methylenecyclopropane)acetyl-Co-A"
- 3/18/93 Department of Chemistry, National Tsing-Hua University, "Mechanistic Study of the Inactivation of Medium Chain Acyl-CoA Dehydrogenase by (methylenecyclopropane)acetyl-Co-A"
- 3/22/93 Department of Chemistry, National Taiwan University, "Mechanistic Study of the Inactivation of Medium Chain Acyl-CoA Dehydrogenase by (methylenecyclopropane)acetyl-Co-A"
- 2/13/95 Department of Chemistry, National Taiwan University, "Characterization of a Stable, Novel Norcaradiene Adduct Resulting from the Inactivation of Thymine Hydroxylase by 5-Ethynyluracil"
- 2/16/95 Department of Life Science, National Tsing-Hua University, "Characterization of a Stable, Novel Norcaradiene Adduct Resulting from the Inactivation of Thymine Hydroxylase by 5-Ethynyluracil"
- 2/22/95 Department of Chemistry, National Taiwan Normal University, "Characterization of a Stable, Novel Norcaradiene Adduct Resulting from the Inactivation of Thymine Hydroxylase by 5-Ethynyluracil"
- 12/8/2003 Protease Targets and Drug Discovery Conference, Strategic Research Institute, "Development of BACE 1 Inhibitors"
- 7/21/2004 Press Release, 9th International Conference on Alzheimer's Disease and Related Disorders, "Development of BACE 1 Inhibitors"